The transplantation of hematopoietic stem cells (THSC) is a therapeutic modality developed
for the treatment of various diseases such as leukemia, bone marrow aplasia, lymphomas,
multiple myeloma, among others. Most patients who undergo the THSC usually have oral
manifestations as a result of immunosuppression achieved by chemotherapy and/or radiotherapy.
The most common complications are the reduction of salivary flow, mucositis and
graft-versus-host disease (GVHD). These conditions can be very debilitating and interfere
with medical therapy, leading to systemic complications, affecting the prognosis and
increasing the length of hospitalization of the patient and the costs of treatment. To date,
there is no protocol that prevents the reduction of salivary flow and minimizes the
occurrence of mucositis and GVHD in these patients. This study aims to verify the
effectiveness of treatment with two sialogogues (Hyperboloid and TENS [transcutaneous
electrical stimulation]) to restore the flow and biochemical composition of saliva in
patients undergoing THSC myeloablative and non-myeloablative conditionating regime.